FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2623589687> ?p ?o ?g. }

• W2623589687 endingPage "1127" @default.
• W2623589687 startingPage "1126" @default.
• W2623589687 abstract "We announce a new series for Addiction on HCV (hepatitis C virus). This is prompted by the changing treatment and prevention landscape and syndemic of HCV and drug use, specifically concerning people who inject drugs (PWID). In some developing countries more than 80% of HCV is among people with a history of drug injection; globally, almost 40% of HCV burden is attributable to injecting drug use and in many countries one in two PWID are likely to be living with HCV 1-3. HCV is an important cause of liver disease, along with alcohol, hepatitis B virus (HBV) and metabolic causes, and the only one that can be cured easily 4. There is no vaccine available for HCV. However, new HCV anti-viral drugs—so-called direct-acting anti-virals (DAAs)—are highly tolerable, of short duration (8–12 weeks) and can cure the disease in the vast majority of cases, with trials involving PWID reporting more than 90% cure rates 5-7. These advancements have raised excitement around the possibility of using HCV treatment as Prevention (TasP). Globally, however, very few PWID are treated for their HCV. Although the cost of DAA therapies can be high, health economic models suggest that prioritizing PWID for early HCV treatment because of the prevention benefits is likely to be cost-effective 8. In addition, there is strengthening empirical evidence that primary prevention interventions such as opioid substitution treatment (OST) and needle and syringe programmes (NSP) can reduce HIV and HCV 9-12. However, theoretical model projections suggest that substantial reductions in HCV transmission among PWID will require both traditional harm reduction/primary prevention and HCV treatment scale-up 13, 14. The ease of administration of these new DAA therapies means that they could be delivered by non-specialists in the community and within drug treatment services, leading to the recommendation that HCV treatment, drug treatment and prevention services should be integrated, which may have advantages and disadvantages in the way that drug treatment services are delivered 15. International clinical guidelines recommend that people at risk of transmitting HCV are treated for HCV 16-18. The World Health Organization Global Health Sector Strategy (GHSS) on Viral Hepatitis has set a challenging goal of eliminating viral hepatitis as a major public health threat by 2030, reducing new chronic infections by 90% and mortality by 65%. In most countries these targets can be achieved only through scaling-up both OST, NSP and HCV treatment for PWID, as highlighted in a recent paper (the first in our series) on HCV in Greece 19. Another model study in our series shows that managing HCV in prisons can make a substantial contribution to reducing transmission in the community 20. Several countries, such as Australia, France, Georgia and Portugal, have already announced and started national HCV elimination campaigns, increasing the number of HCV treatments available and removing any restrictions on access 21, 22. There are great opportunities, therefore, to generate robust evidence on how to prevent HCV transmission and HCV-related morbidity in PWID and in the population. We expect, therefore, as a Commentary in this issue argues, to move from the ‘the theoretical to the empirical sphere’ 23. While these are ambitious goals, success is not guaranteed. Reaching and engaging people with HCV are key challenges, given the prohibition surrounding illicit and injecting drug use and the resultant stigma and discrimination concerns and possible mistrust of health services. Community and peer involvement is likely to be critical to the success of HCV prevention programmes. It has also been hypothesized by some clinicians and researchers that successful treatment of HCV can improve recovery and engagement with drug treatment services 24. The purpose of our new series will be to highlight and document the best new evidence emerging from around the world on the syndemic of HCV and drug use. We are interested in receiving systematic reviews, trials and other evaluations, ethnographic and modelling studies that inform and test how HCV can be prevented in people who use and inject drugs." @default.
• W2623589687 created "2017-06-15" @default.
• W2623589687 creator A5000073653 @default.
• W2623589687 creator A5002616190 @default.
• W2623589687 creator A5007290128 @default.
• W2623589687 creator A5036570109 @default.
• W2623589687 creator A5045529959 @default.
• W2623589687 creator A5048017362 @default.
• W2623589687 creator A5051184153 @default.
• W2623589687 creator A5061560140 @default.
• W2623589687 creator A5069135365 @default.
• W2623589687 creator A5071334665 @default.
• W2623589687 date "2017-06-06" @default.
• W2623589687 modified "2023-10-12" @default.
• W2623589687 title "New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing anAddictionseries" @default.
• W2623589687 cites W1801566764 @default.
• W2623589687 cites W1895949411 @default.
• W2623589687 cites W2051366813 @default.
• W2623589687 cites W2089106363 @default.
• W2623589687 cites W2104563699 @default.
• W2623589687 cites W2133275424 @default.
• W2623589687 cites W2138053911 @default.
• W2623589687 cites W2143398474 @default.
• W2623589687 cites W2167150962 @default.
• W2623589687 cites W2171656281 @default.
• W2623589687 cites W2244659859 @default.
• W2623589687 cites W2345197548 @default.
• W2623589687 cites W2514263904 @default.
• W2623589687 cites W2518041763 @default.
• W2623589687 cites W2518485884 @default.
• W2623589687 cites W2522309098 @default.
• W2623589687 cites W2534316534 @default.
• W2623589687 cites W2555100366 @default.
• W2623589687 cites W2572310633 @default.
• W2623589687 cites W2591797736 @default.
• W2623589687 cites W2621502584 @default.
• W2623589687 cites W971519378 @default.
• W2623589687 doi "https://doi.org/10.1111/add.13847" @default.
• W2623589687 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28586551" @default.
• W2623589687 hasPublicationYear "2017" @default.
• W2623589687 type Work @default.
• W2623589687 sameAs 2623589687 @default.
• W2623589687 citedByCount "2" @default.
• W2623589687 countsByYear W26235896872019 @default.
• W2623589687 crossrefType "journal-article" @default.
• W2623589687 hasAuthorship W2623589687A5000073653 @default.
• W2623589687 hasAuthorship W2623589687A5002616190 @default.
• W2623589687 hasAuthorship W2623589687A5007290128 @default.
• W2623589687 hasAuthorship W2623589687A5036570109 @default.
• W2623589687 hasAuthorship W2623589687A5045529959 @default.
• W2623589687 hasAuthorship W2623589687A5048017362 @default.
• W2623589687 hasAuthorship W2623589687A5051184153 @default.
• W2623589687 hasAuthorship W2623589687A5061560140 @default.
• W2623589687 hasAuthorship W2623589687A5069135365 @default.
• W2623589687 hasAuthorship W2623589687A5071334665 @default.
• W2623589687 hasBestOaLocation W26235896871 @default.
• W2623589687 hasConcept C118552586 @default.
• W2623589687 hasConcept C126322002 @default.
• W2623589687 hasConcept C159047783 @default.
• W2623589687 hasConcept C177713679 @default.
• W2623589687 hasConcept C2522874641 @default.
• W2623589687 hasConcept C27415008 @default.
• W2623589687 hasConcept C2776408679 @default.
• W2623589687 hasConcept C2776455275 @default.
• W2623589687 hasConcept C2778571141 @default.
• W2623589687 hasConcept C2779134260 @default.
• W2623589687 hasConcept C2780035454 @default.
• W2623589687 hasConcept C71924100 @default.
• W2623589687 hasConcept C98274493 @default.
• W2623589687 hasConcept C99454951 @default.
• W2623589687 hasConceptScore W2623589687C118552586 @default.
• W2623589687 hasConceptScore W2623589687C126322002 @default.
• W2623589687 hasConceptScore W2623589687C159047783 @default.
• W2623589687 hasConceptScore W2623589687C177713679 @default.
• W2623589687 hasConceptScore W2623589687C2522874641 @default.
• W2623589687 hasConceptScore W2623589687C27415008 @default.
• W2623589687 hasConceptScore W2623589687C2776408679 @default.
• W2623589687 hasConceptScore W2623589687C2776455275 @default.
• W2623589687 hasConceptScore W2623589687C2778571141 @default.
• W2623589687 hasConceptScore W2623589687C2779134260 @default.
• W2623589687 hasConceptScore W2623589687C2780035454 @default.
• W2623589687 hasConceptScore W2623589687C71924100 @default.
• W2623589687 hasConceptScore W2623589687C98274493 @default.
• W2623589687 hasConceptScore W2623589687C99454951 @default.
• W2623589687 hasIssue "7" @default.
• W2623589687 hasLocation W26235896871 @default.
• W2623589687 hasLocation W26235896872 @default.
• W2623589687 hasLocation W26235896873 @default.
• W2623589687 hasOpenAccess W2623589687 @default.
• W2623589687 hasPrimaryLocation W26235896871 @default.
• W2623589687 hasRelatedWork W1801566764 @default.
• W2623589687 hasRelatedWork W1904462763 @default.
• W2623589687 hasRelatedWork W2007824547 @default.
• W2623589687 hasRelatedWork W2014276866 @default.
• W2623589687 hasRelatedWork W2021392205 @default.
• W2623589687 hasRelatedWork W2022024489 @default.
• W2623589687 hasRelatedWork W2304421451 @default.
• W2623589687 hasRelatedWork W2771509167 @default.

• next